Filters
Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy
Correlation of CD33 with poorer prognosis in childhood ALL implicates a potential of anti-CD33 frontline therapy...
FD - Onkologie a hematologie
- 2005 •
- Jx
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
CD33 (HIM3-4) Pacific Blue
Monoclonal antibody to CD33 membrane antigen (HIM3-4) labelled by Pacific Blue...
EI - Biotechnologie a bionika
- 2009 •
- Ztech
Rok uplatnění
Ztech - Ověřená technologie
CD33 (HIM3-4) PE-Dyomics 647
Monoclonal antibody to CD33 membrane antigen (HIM3-4) labelled by PE-Dyomics 647...
EI - Biotechnologie a bionika
- 2009 •
- Ztech
Rok uplatnění
Ztech - Ověřená technologie
Gemtuzumab ozogamicin with Midostaurin in the intensive treatment of CD33/FLT3+ AML - updated data
Gemtuzumab ozogamicin with Midostaurin in the intensive treatment of CD33/FLT3+ AML - updated data - conference abstract.
Hematology
- 2023 •
- O
Rok uplatnění
O - Ostatní výsledky
Comment: gemtuzumab ozogamicin
Despite the large number of new, targeted drugs in oncology, acute myeloid leukemia has been behind the interests of pharmaceutical development for decades. In 2000, the US Food and Drug Administration approved gemtuzumab ozogamicin for the treatment...
Hematology
- 2020 •
- Jost •
- Link
Rok uplatnění
Jost - Ostatní články v recenzovaných periodicích
Výsledek na webu
Human Monocyte-Derived Suppressor Cell Supernatant Induces Immunoregulatory Effects and Mitigates xenoGvHD
to generate human monocyte-derived suppressor Cells (HuMoSC), a subpopulation of CD33+ suppressor cells of monocytic origin. CD33+HuMoSC successfully reduced xenoGvHD severity in NOD/SCID/IL-2R gamma c(-/-) (NSG) mice. While CD...
Immunology
- 2022 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Gemtuzumab ozogamicin plus midostaurin in conjunction with standard intensive therapy for FLT3-mutated acute myeloid leukemia patients – Czech center experience
the use of novel and effective, target-directed therapies, including the anti-CD33 on a homogeneous cohort of patients with FLT3-mutated/CD33+ AML treated with GO + midostaurin added to standard IC in patients with newly diagnosed ...
Hematology
- 2023 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
Biological drugs in hematooncology
... Gemtuzumab ozogamicin is an anti-CD33 antibody with bonded enediyn antibiotic...
FD - Onkologie a hematologie
- 2012 •
- C
Rok uplatnění
C - Kapitola v odborné knize
CD34+/CD41a+, CD34+/AC133+, CD34+/CD33- examination in cryopreserved peripheral stem cells concentrates suitable for improving the recovery prediction of hematopoesis after transplantation
The method is relatively simple, reliable, not much time consuming. It is necessary to have good experience with the method of cell isolation and flow cytometry....
FD - Onkologie a hematologie
- 2002 •
- Jx
Rok uplatnění
Jx - Nezařazeno - Článek v odborném periodiku (Jimp, Jsc a Jost)
Celiac disease defined by over-sensitivity to gliadin activation and superior antigen presentation of dendritic cells
a novel bio-profile characterised by elevated CD64 and reduced CD33 levels, unique...
Immunology
- 2021 •
- Jimp •
- Link
Rok uplatnění
Jimp - Článek v periodiku v databázi Web of Science
Výsledek na webu
- 1 - 10 out of 25